Drug Profile
Intranasal influenza virus vaccine - BlueWillow Biologics
Alternative Names: H5N1 Influenza vaccine; NanoVax®-Panflu; NE-rH5 vaccineLatest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 29 Dec 2022 Phase I development for Influenza virus infections is ongoing in USA
- 07 Jul 2022 BlueWillow Biologics initiates the phase I IN-NE-rH5 trial for Influenza virus infections (Prevention, In volunteers) in USA (NCT05397119)
- 31 May 2022 BlueWillow Biologics plans a phase I trial for Influenza virus infections (Prevention, In adults) in USA (NCT05397119; BW-1014-001; 20-0036)